These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 30356816)

  • 1. The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent.
    Grasselly C; Denis M; Bourguignon A; Talhi N; Mathe D; Tourette A; Serre L; Jordheim LP; Matera EL; Dumontet C
    Front Immunol; 2018; 9():2100. PubMed ID: 30356816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
    Reyes RM; Deng Y; Zhang D; Ji N; Mukherjee N; Wheeler K; Gupta HB; Padron AS; Kancharla A; Zhang C; Garcia M; Kornepati AVR; Boyman O; Conejo-Garcia JR; Svatek RS; Curiel TJ
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
    Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
    FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
    Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
    J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.
    Tu J; Xu H; Ma L; Li C; Qin W; Chen X; Yi M; Sun L; Liu B; Yuan X
    Theranostics; 2022; 12(2):747-766. PubMed ID: 34976211
    [No Abstract]   [Full Text] [Related]  

  • 6. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
    Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
    Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
    Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
    Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
    Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced systemic antitumor efficacy of PD-1/PD-L1 blockade with immunological response induced by photodynamic therapy.
    Sonokawa T; Fujiwara Y; Pan C; Komohara Y; Usuda J
    Thorac Cancer; 2024 Jun; 15(18):1429-1436. PubMed ID: 38739102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
    Yoneda K; Imanishi N; Ichiki Y; Tanaka F
    J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination therapy of Everolimus and anti-PD-1 improves the antitumor effect by regulating CD8
    Xia W; Zhang S; Duan H; Wang C; Qian S; Shen H
    Med Oncol; 2022 Jan; 39(3):37. PubMed ID: 35059863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoscale Reduced Graphene Oxide-Mediated Photothermal Therapy Together with IDO Inhibition and PD-L1 Blockade Synergistically Promote Antitumor Immunity.
    Yan M; Liu Y; Zhu X; Wang X; Liu L; Sun H; Wang C; Kong D; Ma G
    ACS Appl Mater Interfaces; 2019 Jan; 11(2):1876-1885. PubMed ID: 30582788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
    Xu C; Zhang Y; Rolfe PA; Hernández VM; Guzman W; Kradjian G; Marelli B; Qin G; Qi J; Wang H; Yu H; Tighe R; Lo KM; English JM; Radvanyi L; Lan Y
    Clin Cancer Res; 2017 Oct; 23(19):5869-5880. PubMed ID: 28679778
    [No Abstract]   [Full Text] [Related]  

  • 19. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
    Bissonnette RP; Cesario RM; Goodenow B; Shojaei F; Gillings M
    BMC Cancer; 2021 Aug; 21(1):969. PubMed ID: 34461854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.